Detailed Information on Publication Record
2012
Measuring diffuse metabolic activity on FDG-PET/CT: new method for evaluating Langerhans cell histiocytosis activity in pulmonary parenchyma
SZTURZ, Petr, Zdeněk ŘEHÁK, Renata KOUKALOVÁ, Zdeněk ADAM, Marta KREJČÍ et. al.Basic information
Original name
Measuring diffuse metabolic activity on FDG-PET/CT: new method for evaluating Langerhans cell histiocytosis activity in pulmonary parenchyma
Authors
SZTURZ, Petr (203 Czech Republic, guarantor, belonging to the institution), Zdeněk ŘEHÁK (203 Czech Republic), Renata KOUKALOVÁ (203 Czech Republic), Zdeněk ADAM (203 Czech Republic, belonging to the institution), Marta KREJČÍ (203 Czech Republic, belonging to the institution), Luděk POUR (203 Czech Republic, belonging to the institution), Lenka ZAHRADOVÁ (203 Czech Republic, belonging to the institution), Jiří VANÍČEK (203 Czech Republic, belonging to the institution), Tomáš NEBESKÝ (203 Czech Republic, belonging to the institution), Roman HÁJEK (203 Czech Republic, belonging to the institution) and Jiří MAYER (203 Czech Republic, belonging to the institution)
Edition
Nuclear Medicine and Biology, 2012, 0969-8051
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30200 3.2 Clinical medicine
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 2.517
RIV identification code
RIV/00216224:14110/12:00059813
Organization unit
Faculty of Medicine
UT WoS
000301961700012
Keywords in English
Langerhans cell histiocytosis; Interstitial lung disease; Positron emission tomography; Pulmonary function tests; High-resolution computed tomography (HRCT)
Tags
International impact
Změněno: 1/10/2018 11:58, Soňa Böhmová
Abstract
V originále
Pulmonary Langerhans cell histiocytosis (PLCH) is a rare cause of interstitial lung disease characterized by formation of nodules in the active phase of the disease that evolve into nonactive cystic lesions later on. To evaluate PLCH activity in patients, we developed a new method for measuring diffuse metabolic activity on fluorine-18-fluorodeoxyglucose positron emission tomography/ computed tomography (FDG-PET/CT) using a lung-to-liver activity ratio. Material and Methods: We retrospectively studied a series of 4 FDG-PET and 23 FDG-PET/CT scans from 7 patients with PLCH and analyzed a sample of 100 randomly chosen FDG-PET/CT studies free from any known lung or hepatic diseases. Maximum standardized uptake value (SUVmax) in a spherical volume (6–8 cm in diameter) in the right lung was put into relation with SUVmax in a spherical volume (9–10 cm in diameter) in the reference liver parenchyma to set up the SUVmaxPULMO/SUVmaxHEPAR index. The index values were compared to the disease course in each patient. Results: In patients with PLCH, a close correlation between the index value and the disease course was found in all seven subjects, where the increasing index values indicated disease activity, while decreasing index values were observed after therapy administration. In the group of 100 healthy control subjects, we found index values lower than 0.3 in 80% and lower than 0.4 in 96%. Conclusion: Measuring SUVmaxPULMO/SUVmaxHEPAR values and their time-trend monitoring represent simple, noninvasive screening tools allowing an early diagnosis and treatment response follow-up assessment in patients with PLCH.
Links
| LC06027, research and development project |
| ||
| MSM0021622434, plan (intention) |
| ||
| NS9671, research and development project |
| ||
| NT11154, research and development project |
|